Expression of the H-ras Proto-oncogene is Controlled by Alternative Splicing
Overview
Authors
Affiliations
We previously demonstrated that a point mutation in the last intron of the human H-ras oncogene causes a significant increase in its expression and transforming efficiency. Here we establish the basis of this phenomenon. Using gene reconstruction experiments, we have identified a negative-acting element in the intron that is completely inactivated by the mutation. The effects of other nucleotide alterations introduced into this region suggested that the negative element might constitute an alternative exon. Transcripts containing this putative exon were identified and S1 nuclease analysis confirmed that the mutation prevents their synthesis. The abundance of these transcripts is low, apparently due to message instability and/or defective processing. The predicted product of the alternative transcript is suggested to lack transforming potential. Our findings demonstrate that alternative splicing normally operates to suppress p21H-ras expression and that this negative control is abolished by a variety of mutations that interfere with this process.
Chen X, Yang H, Zhang B, Phillips J, Cheng D, Rigo F Proc Natl Acad Sci U S A. 2023; 120(28):e2220190120.
PMID: 37399401 PMC: 10334793. DOI: 10.1073/pnas.2220190120.
Origin and Evolution of RAS Membrane Targeting.
Garcia-Espana A, Philips M Oncogene. 2023; 42(21):1741-1750.
PMID: 37031342 PMC: 10413328. DOI: 10.1038/s41388-023-02672-z.
Origin and evolution of RAS oncoprotein membrane targeting.
Garcia-Espana A, Philips M Res Sq. 2023; .
PMID: 36711820 PMC: 9882654. DOI: 10.21203/rs.3.rs-2485219/v1.
Das A, Sherry E, Vaughan R, Henderson M, Zieba J, Uhl K Front Cell Dev Biol. 2022; 10:1033695.
PMID: 36467401 PMC: 9714508. DOI: 10.3389/fcell.2022.1033695.
MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors.
Urbanski L, Brugiolo M, Park S, Angarola B, Leclair N, Yurieva M Cell Rep. 2022; 41(8):111704.
PMID: 36417849 PMC: 9731204. DOI: 10.1016/j.celrep.2022.111704.